(NASDAQ: ORIC) Oric Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.58%.
Oric Pharmaceuticals's earnings in 2025 is -$135,270,000.On average, 17 Wall Street analysts forecast ORIC's earnings for 2025 to be -$154,537,308, with the lowest ORIC earnings forecast at -$164,159,369, and the highest ORIC earnings forecast at -$151,342,940. On average, 17 Wall Street analysts forecast ORIC's earnings for 2026 to be -$154,712,609, with the lowest ORIC earnings forecast at -$242,616,172, and the highest ORIC earnings forecast at -$124,755,666.
In 2027, ORIC is forecast to generate -$160,517,010 in earnings, with the lowest earnings forecast at -$197,466,502 and the highest earnings forecast at -$122,710,492.